


Munich Cancer Registry



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

BNET: Pulm. neuroend. tumor

Incidence and Mortality

Year of diagnosis	1998-2019
Patients	1,188
Diseases	1,190
Creation date	01/26/2021
Database export	01/07/2021
Population	4.92 m



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

<https://www.tumorregister-muenchen.de/en/facts/base/bhBNETE-BNET-Pulm.-neuroend.-tumor-incidence-and-mortality.pdf>

Index of figures and tables

Fig./Tbl.		Page
1	Annual cases, mult. malignancies, follow-up / yr	5
2	Incidence by year of diagnosis	8
3	Age distribution parameters by year of diagnosis	9
4	Age distribution by 5-year age group and sex	12
5	Age-specific incidence, proportion malignancies	13
6	Age distribution and age-specific incidence (chart)	14
6a	Age-specific incidence internationally (chart)	15
7	Standardized incidence ratio of further malignancies	16
8a	Map of cancer incidence (BRD-S) by county (chart)	18
8b	Standardized incidence ratio (SIR) by county (chart)	19
9a	Pts incident cohorts and mortality / yr	20
9b	Incidence and mortality by year of diagnosis	21
9c	Cancer-related deaths, death certification available / yr	22
10	Medians of age at death / yr	23
11	Mortality by year of death	25
12	Distribution of age at death	27
13	Age-specific mortality	28
14	Further malignancies in deaths	29
15	Age-specific mortality (first primaries)	31
16	Age-specific mortality (single primaries)	32
17	Age distribution and age-specific mortality (chart)	33
18a	Map of cancer mortality (BRD-S) by county (chart)	34
18b	Standardized mortality ratio (SMR) by county (chart)	35

**Global Statements about the statistics on the Internet –
Baseline Statistics** (grey button ) , **Survival** (red button )

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.69 million inhabitants, account for the frequency of cancer diseases^{##} and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases^{###} are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, January 2021

- [#] Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.65 million to 4.10 in 2002, and to 4.69 million in 2007).
- ^{##} Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- ^{###} DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate.

Topography codes (ICD-O-3 2000) used for specifying cancer site

Code	Description
C33	Malignant neoplasm of trachea
C34.-	Malignant neoplasm of bronchus and lung
C34.0	Main bronchus
C34.1	Upper lobe, bronchus or lung
C34.2	Middle lobe, bronchus or lung
C34.3	Lower lobe, bronchus or lung
C34.8	Overlapping lesion of bronchus and lung
C34.9	Bronchus or lung, unspecified

... if additionally existing any of ...

Morphology codes (ICD-O-3 2011) used for specifying cancer site

Code	Description
8013/3	Large cell neuroendocrine carcinoma
8240/3	Carcinoid tumor, NOS
8249/3	Atypical carcinoid tumor

Reference:

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC, Lyon (2004).

INCIDENCE

Table 1

Cases with invasive cancer by year of diagnosis, proportions of further malignancies, deaths, and active follow-up (ALL PATIENTS)

Year of diagnosis	All cases n	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	12	8.3	7.7	50.0	83.3
1999	23	14.3	7.6	65.2	95.7
2000	21	16.1	7.6	57.1	100.0
2001	21	14.3	7.4	66.7	100.0
2002	25	13.7	7.4	56.0	92.0 #
2003	22	13.7	7.2	59.1	95.5
2004	29	13.7	7.2	55.2	96.6
2005	30	14.8	7.2	40.0	86.7
2006	30	13.6	7.1	43.3	93.3
2007	41	13.0	6.7	61.0	92.7 #
2008	61	15.9	6.6	49.2	98.4
2009	57	16.7	5.8	43.9	93.0
2010	51	18.0	5.2	56.9	96.1
2011	77	17.6	4.8	46.8	97.4
2012	73	18.5	4.0	57.5	97.3
2013	78	20.1	4.2	59.0	98.7
2014	96	20.2	3.4	52.1	96.9
2015	87	21.0	2.8	50.6	96.6
2016	97	21.2	2.9	35.1	100.0
2017	94	21.0	2.0	43.6	100.0
2018	96	21.2	1.3	33.3	100.0
2019	69	21.8	0.0	21.7	81.2 ##
1998-2019	1190	21.8	7.7	47.4	96.1

1,190 cases diagnosed 1998-2019 are related to a total of 1,188 patients. Currently, in 349 (29.4 %) of these 1,188 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 271 / 62 / 16 (22.8 % / 5.2 % / 1.3 %) patients exist having 2 / 3 / 4+ malignancies.

The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2017, a subgroup of 94 cases has been diagnosed, of which 21.0 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 2.0 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1a

Cases with invasive cancer by year of diagnosis, proportions of further malignancies, deaths, and active follow-up (MALES)

Year of diagnosis	Males n	Males %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	6	50.0	0.0	6.9	83.3	83.3
1999	11	47.8	11.8	6.8	63.6	100.0
2000	8	38.1	16.0	6.6	75.0	100.0
2001	14	66.7	12.8	6.5	71.4	100.0
2002	12	48.0	15.7	6.7	75.0	100.0 #
2003	9	40.9	15.0	6.4	77.8	100.0
2004	14	48.3	14.9	6.3	57.1	100.0
2005	17	56.7	16.5	6.5	47.1	94.1
2006	18	60.0	15.6	6.3	61.1	94.4
2007	24	58.5	15.0	5.9	66.7	91.7 #
2008	29	47.5	16.0	5.8	69.0	96.6
2009	26	45.6	16.0	5.0	53.8	96.2
2010	29	56.9	18.4	4.6	69.0	93.1
2011	40	51.9	17.5	4.4	62.5	95.0
2012	37	50.7	18.7	4.0	73.0	100.0
2013	42	53.8	19.6	4.1	69.0	100.0
2014	48	50.0	20.1	2.4	56.3	100.0
2015	41	47.1	19.5	2.0	56.1	97.6
2016	40	41.2	19.8	2.5	35.0	100.0
2017	47	50.0	19.5	0.8	48.9	100.0
2018	50	52.1	19.8	0.0	42.0	100.0
2019	32	46.4	19.9	0.0	37.5	84.4 ##
1998-2019	594	49.9	19.9	6.9	57.6	97.1

594 cases diagnosed 1998-2019 are related to a total of 593 patients. Currently, in 162 (27.3 %) of these 593 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 127 / 28 / 7 (21.4 % / 4.7 % / 1.2 %) patients exist having 2 / 3 / 4+ malignancies.

The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2017, a subgroup of 47 cases has been diagnosed, of which 19.5 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 0.8 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 1b

Cases with invasive cancer by year of diagnosis, proportions of further malignancies, deaths, and active follow-up (FEMALES)

Year of diagnosis	Females n	Females %	Prop. at least 1 further malign. prior + synchron. %	Prop. at least 1 further malign. after %	Prop. deaths %	Prop. actively followed %
1998	6	50.0	16.7	8.4	16.7	83.3
1999	12	52.2	16.7	8.3	66.7	91.7
2000	13	61.9	16.1	8.5	46.2	100.0
2001	7	33.3	15.8	8.3	57.1	100.0
2002	13	52.0	11.8	8.1	38.5	84.6 #
2003	13	59.1	12.5	7.9	46.2	92.3
2004	15	51.7	12.7	8.1	53.3	93.3
2005	13	43.3	13.0	7.9	30.8	76.9
2006	12	40.0	11.5	7.9	16.7	91.7
2007	17	41.5	10.7	7.5	52.9	94.1 #
2008	32	52.5	15.7	7.3	31.3	100.0
2009	31	54.4	17.4	6.5	35.5	90.3
2010	22	43.1	17.5	5.7	40.9	100.0
2011	37	48.1	17.7	5.3	29.7	100.0
2012	36	49.3	18.3	4.1	41.7	94.4
2013	36	46.2	20.6	4.2	47.2	97.2
2014	48	50.0	20.4	4.4	47.9	93.8
2015	46	52.9	22.5	3.5	45.7	95.7
2016	57	58.8	22.5	3.3	35.1	100.0
2017	47	50.0	22.4	3.1	38.3	100.0
2018	46	47.9	22.7	2.5	23.9	100.0
2019	37	53.6	23.7	0.0	8.1	78.4 ##
1998-2019	596	50.1	23.7	8.4	37.2	95.0

596 cases diagnosed 1998-2019 are related to a total of 595 patients. Currently, in 187 (31.4 %) of these 595 patients more than one malignancy of any cancer type has been registered. Hereby, groups of 144 / 34 / 9 (24.2 % / 5.7 % / 1.5 %) patients exist having 2 / 3 / 4+ malignancies.

The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

Please be aware that data of recent annual patient cohorts may not yet be fully processed. The years under evaluation can be retrieved from the respective headings.

How to interpret:

In 2017, a subgroup of 47 cases has been diagnosed, of which 22.4 % previously and/or concurrently (synchronously) had at least one other malignancy of any cancer type. In 3.1 % of cases, at least one new malignancy has occurred during the follow-up period (all numbers refer to the date of the database export, see cover sheet).

Table 2

Incidence measures by year of diagnosis
(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,
and from 4.10 to 4.92 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	6	6	0.5	0.5	0.4	0.3	0.5	0.4	0.6	0.5
1999	11	12	1.0	1.0	0.6	0.5	0.9	0.7	1.1	0.9
2000	8	13	0.7	1.1	0.4	0.8	0.6	1.0	0.7	1.1
2001	14	7	1.2	0.6	0.9	0.4	1.1	0.5	1.3	0.5
2002	12	13	0.6	0.7	0.4	0.4	0.6	0.6	0.7	0.6
2003	9	13	0.5	0.7	0.3	0.4	0.4	0.5	0.5	0.6
2004	14	15	0.7	0.8	0.4	0.5	0.6	0.6	0.7	0.7
2005	17	13	0.9	0.7	0.7	0.5	0.9	0.6	0.9	0.6
2006	18	12	0.9	0.6	0.5	0.4	0.7	0.5	0.9	0.6
2007	24	17	1.1	0.7	0.7	0.4	0.9	0.6	1.1	0.7
2008	29	32	1.3	1.4	0.7	0.8	1.0	1.1	1.2	1.3
2009	26	31	1.2	1.3	0.7	0.8	1.0	1.1	1.1	1.2
2010	29	22	1.3	0.9	0.7	0.6	1.0	0.7	1.2	0.8
2011	40	37	1.8	1.6	1.0	0.9	1.4	1.2	1.7	1.4
2012	37	36	1.6	1.5	0.9	0.8	1.3	1.1	1.5	1.3
2013	42	36	1.8	1.5	1.0	0.8	1.4	1.1	1.6	1.2
2014	48	48	2.1	2.0	1.1	1.1	1.5	1.4	1.8	1.7
2015	41	46	1.7	1.9	0.9	0.9	1.4	1.3	1.6	1.6
2016	40	57	1.7	2.3	0.9	1.3	1.3	1.7	1.5	2.0
2017	47	47	1.9	1.9	1.0	0.9	1.4	1.3	1.7	1.6
2018	50	46	2.1	1.9	1.0	1.1	1.5	1.4	1.8	1.6
2019	32	37	1.3	1.5	0.6	0.9	0.9	1.1	1.2	1.3
1998-2019	594	596	1.3	1.3	0.8	0.7	1.1	1.0	1.3	1.1

The computation of the incidence measures includes all cancers, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (ALL PATIENTS)

Year of diagnosis	Cases n	Std.		Median						
		Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	12	60.1	8.0	49.4	70.9	50.9	51.9	60.3	68.3	69.6
1999	23	64.3	13.8	32.9	81.2	45.5	54.6	67.2	76.7	78.9
2000	21	59.2	15.8	15.8	80.5	44.9	52.5	63.2	71.3	74.9
2001	21	56.2	17.1	17.0	79.8	31.3	41.3	62.2	69.3	70.7
2002	25	63.1	13.4	31.0	82.8	48.2	53.9	67.4	74.9	75.6
2003	22	63.6	10.6	43.9	84.4	49.4	60.1	63.2	72.7	79.5
2004	29	58.8	15.2	27.6	84.1	37.8	47.8	62.6	69.2	78.6
2005	30	51.6	16.1	18.1	82.9	26.9	41.6	52.2	64.9	70.7
2006	30	59.0	15.9	27.5	82.6	32.8	47.3	61.0	70.6	79.0
2007	41	60.0	17.0	18.7	84.2	39.9	47.5	65.8	72.1	79.2
2008	61	63.2	12.9	29.4	88.0	41.7	59.3	64.6	71.7	77.0
2009	57	62.5	12.0	25.9	89.3	48.1	55.8	62.7	70.1	76.7
2010	51	63.2	12.4	15.6	82.0	47.5	56.0	66.0	71.0	75.2
2011	77	63.4	12.2	33.0	85.6	46.7	55.5	63.0	71.5	80.5
2012	73	66.6	10.4	39.5	89.1	54.3	58.9	68.7	74.2	78.1
2013	78	65.9	10.2	36.7	85.4	51.4	58.8	67.8	73.2	78.9
2014	96	65.3	13.0	15.9	85.2	48.1	58.0	66.7	74.2	79.7
2015	87	65.2	12.1	23.7	86.6	51.0	57.0	65.5	75.0	79.3
2016	97	63.8	13.7	20.9	91.0	47.8	55.7	65.1	73.8	79.1
2017	94	66.5	12.4	24.2	85.5	53.4	58.4	68.4	77.5	81.0
2018	96	63.8	16.0	18.5	86.6	38.5	55.6	67.4	74.6	82.4
2019	69	66.6	13.5	19.7	89.1	48.8	61.0	67.7	76.8	80.0
1998-2019	1190	63.6	13.5	15.6	91.0	46.5	56.0	65.3	73.1	79.4

Table 3a

Age distribution parameters by year of diagnosis (MALES)

Year of diagnosis	Cases n	Std.		Min.		Max.		Median		
		Mean	dev.			10%	25%	50%	75%	90%
1998	6	57.4	10.0	49.4	70.9	49.4	50.9	51.9	69.6	70.9
1999	11	63.4	13.2	38.6	80.4	45.5	53.5	66.2	74.2	78.9
2000	8	58.7	9.9	44.9	77.6	44.9	53.2	56.6	64.0	77.6
2001	14	56.5	19.5	17.0	79.8	29.8	38.4	65.1	70.7	72.6
2002	12	66.7	10.6	49.8	82.8	53.5	57.3	69.4	74.9	75.4
2003	9	63.5	12.3	49.4	84.4	49.4	53.2	62.7	65.5	84.4
2004	14	58.3	14.6	37.8	80.5	38.9	41.0	60.6	69.2	78.6
2005	17	50.9	15.8	18.1	71.2	21.7	42.5	52.3	64.9	70.1
2006	18	62.4	15.4	28.7	82.6	35.1	56.4	66.2	72.3	80.9
2007	24	61.3	15.9	18.7	80.7	44.2	53.7	65.9	72.1	79.2
2008	29	65.0	12.3	32.3	88.0	41.3	60.2	66.8	72.3	80.1
2009	26	61.4	9.5	30.8	76.7	52.2	55.8	62.6	69.0	70.6
2010	29	63.6	14.7	15.6	82.0	43.8	54.6	69.3	72.7	81.7
2011	40	65.1	11.8	34.4	83.0	50.0	57.1	66.4	74.6	80.7
2012	37	66.9	9.7	44.0	85.1	55.5	60.4	68.2	74.1	81.9
2013	42	65.9	10.3	36.7	82.5	51.7	58.6	66.6	73.5	79.2
2014	48	65.2	10.6	37.3	84.1	49.4	56.5	66.1	73.6	78.6
2015	41	63.8	11.1	38.2	86.6	51.2	57.0	61.2	72.6	77.0
2016	40	64.3	13.4	25.5	91.0	48.2	56.7	66.1	73.8	78.3
2017	47	65.5	12.4	28.7	82.2	51.8	57.0	66.4	76.5	81.0
2018	50	66.7	14.3	24.7	86.3	49.6	59.3	68.6	77.3	83.5
2019	32	70.4	11.5	40.6	89.1	57.1	62.7	72.0	79.0	80.3
1998-2019	594	64.1	12.9	15.6	91.0	48.1	56.6	65.7	73.2	79.5

Table 3b

Age distribution parameters by year of diagnosis (FEMALES)

Year of diagnosis	Cases n	Std.		Min.	Max.	Median				
		Mean	dev.			10%	25%	50%	75%	90%
1998	6	62.8	4.7	56.6	68.7	56.6	59.9	61.8	67.8	68.7
1999	12	65.2	14.8	32.9	81.2	47.0	56.8	71.6	77.1	78.4
2000	13	59.5	19.0	15.8	80.5	29.3	52.5	67.2	72.2	74.9
2001	7	55.6	12.2	38.0	69.3	38.0	41.3	55.5	66.9	69.3
2002	13	59.8	15.3	31.0	76.2	33.6	51.4	65.9	72.8	75.6
2003	13	63.7	9.8	43.9	79.5	49.2	60.4	63.8	72.7	73.0
2004	15	59.3	16.2	27.6	84.1	29.9	47.8	64.9	69.4	73.2
2005	13	52.6	16.9	21.6	82.9	32.2	41.6	49.6	58.8	77.4
2006	12	54.0	15.8	27.5	78.6	30.4	43.8	56.6	63.9	74.3
2007	17	58.3	18.7	22.3	84.2	29.1	43.9	59.7	72.9	81.5
2008	32	61.6	13.3	29.4	79.9	41.7	56.1	64.3	71.6	75.8
2009	31	63.4	13.8	25.9	89.3	47.2	55.6	62.7	72.7	79.5
2010	22	62.6	8.8	39.9	75.8	51.2	60.0	65.3	68.3	71.8
2011	37	61.5	12.5	33.0	85.6	45.9	53.4	61.5	68.1	80.4
2012	36	66.2	11.3	39.5	89.1	51.2	56.6	69.0	75.1	76.9
2013	36	65.8	10.1	45.0	85.4	51.4	59.3	68.2	73.1	78.2
2014	48	65.4	15.1	15.9	85.2	43.9	59.9	68.7	75.1	81.8
2015	46	66.5	12.9	23.7	84.8	48.6	57.0	69.6	77.4	79.6
2016	57	63.4	14.0	20.9	87.0	44.4	55.2	64.9	73.8	79.1
2017	47	67.4	12.5	24.2	85.5	53.7	59.3	68.7	78.6	81.0
2018	46	60.6	17.2	18.5	86.6	29.5	51.3	64.7	72.1	81.0
2019	37	63.4	14.3	19.7	89.0	46.3	59.9	66.0	71.3	79.6
1998-2019	596	63.1	14.0	15.8	89.3	43.9	55.6	64.9	73.0	79.3

Table 4

Age distribution by 5-year age group and sex for period 2007-2019

Age at diagnosis Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4									
5-9									
10-14									
15-19	5	0.5	0.5	2	0.4	0.4	3	0.6	0.6
20-24	5	0.5	1.0	1	0.2	0.6	4	0.8	1.4
25-29	12	1.2	2.3	3	0.6	1.2	9	1.8	3.3
30-34	15	1.5	3.8	7	1.4	2.7	8	1.6	4.9
35-39	12	1.2	5.0	5	1.0	3.7	7	1.4	6.3
40-44	26	2.7	7.7	11	2.3	6.0	15	3.0	9.3
45-49	36	3.7	11.4	17	3.5	9.5	19	3.9	13.2
50-54	76	7.8	19.1	35	7.2	16.7	41	8.3	21.5
55-59	121	12.4	31.5	68	14.0	30.7	53	10.8	32.3
60-64	156	16.0	47.5	74	15.3	46.0	82	16.7	49.0
65-69	143	14.6	62.1	68	14.0	60.0	75	15.2	64.2
70-74	159	16.3	78.4	92	19.0	79.0	67	13.6	77.8
75-79	119	12.2	90.6	57	11.8	90.7	62	12.6	90.4
80-84	71	7.3	97.9	35	7.2	97.9	36	7.3	97.8
85+	21	2.1	100.0	10	2.1	100.0	11	2.2	100.0
All ages	977	100.0		485	100.0		492	100.0	

Table 5

Age-specific incidence and proportion of all cancers for period 2007-2019

Age at diagnosis Years	Males n	Females n	Males Age- spec. incid.	Females Age- spec. incid.	Males Prop.all cancers n=143063 %	Females Prop.all cancers n=144724 %
0- 4						
5- 9						
10-14						
15-19	2	3	0.1	0.2	0.7	1.2
20-24	1	4	0.1	0.2	0.2	0.8
25-29	3	9	0.1	0.4	0.3	0.8
30-34	7	8	0.3	0.4	0.6	0.4
35-39	5	7	0.2	0.3	0.3	0.2
40-44	11	15	0.5	0.7	0.4	0.3
45-49	17	19	0.7	0.8	0.4	0.2
50-54	35	41	1.5	1.8	0.4	0.4
55-59	68	53	3.5	2.7	0.6	0.4
60-64	74	82	4.5	4.7	0.5	0.6
65-69	68	75	4.5	4.5	0.3	0.4
70-74	92	67	6.6	4.2	0.4	0.4
75-79	57	62	5.1	4.5	0.3	0.3
80-84	35	36	5.3	3.7	0.2	0.3
85+	10	11	2.3	1.1	0.1	0.1
All ages	485	492			0.3	0.3
Incidence						
Raw			1.6	1.6		
WS			0.9	0.9		
ES			1.2	1.2		
BRD-S			1.5	1.4		

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

BNET: Bronchopulmonary neuroendocrine tumor (excl. SCLC)

Age distribution and age-specific incidence 2007 - 2019 (Males: 485, Females: 492)




Figure 6. Age distribution (males: mean=65.2 yrs, median=66.7 yrs; females: mean=63.9 yrs, median=65.4 yrs) and age-specific incidence.




Figure 6a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2019, based on the November 2018 submission. <http://www.seer.cancer.gov>.

Table 7a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of further malignancies for period 1998–2019

MALES

Diagnosis	Observed n	Expected n	SIR	CI 95%	CI 95%	EAR	DCO %
C09–C10 Oropharynx	2	0.2	9.0	1.1	32.4 #	12.3	
C16 Stomach	4	0.7	5.4	1.5	13.9 #	22.5	
C17 Small intestine	2	0.1	16.2	2.0	58.4 #	12.9	
C18 Colon	5	1.8	2.8	0.9	6.4	22.0	
C19–C20 Rectum	3	1.0	2.9	0.6	8.5	13.6	
C22 Liver	2	0.6	3.4	0.4	12.4	9.8	
C23–C24 Bile	2	0.2	9.8	1.2	35.3 #	12.4	
C32 Larynx	2	0.2	9.9	1.2	35.9 #	12.4	
C33–C34 Lung	16	2.3	6.8	3.9	11.1 #	94.2	
C43 Malign. melanoma	3	0.9	3.3	0.7	9.7	14.5	
C48 Peritoneal	1	0.0	61.9	1.6	345.0 #	6.8	
C61 Prostate	6	5.4	1.1	0.4	2.4	4.1	
C64 Kidney	3	0.7	4.4	0.9	12.8	16.0	
C67 Bladder	3	0.9	3.5	0.7	10.2	14.7	
C70–C72 CNS cancer	1	0.3	3.9	0.1	22.0	5.1	
C82–C85 NHL	1	0.8	1.2	0.0	6.9	1.3	
C90 Mult. myeloma	1	0.2	4.0	0.1	22.4	5.2	
Not observed	0	3.2	0.0	0.0	1.2	-21.9	
All further malignancies	57	19.6	2.9	2.2	3.8 #	257.8	
Patients		572					
Median age at next malignancy (years)		70.8					
Person-years		1450					
Mean observation time (years)		2.5					
Median observation time (years)		0.9					

The occurrence of further specified malignancy is statistically significant.

Table 7b


Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of further malignancies
for period 1998–2019

FEMALES

Diagnosis	Observed n	Expected n	SIR	CI 95%	CI 95%	EAR	DCO %
C16 Stomach	2	0.4	4.5	0.5	16.3	9.6	
C17 Small intestine	1	0.1	11.0	0.3	61.2	5.6	
C18 Colon	1	1.3	0.8	0.0	4.2	-2.0	
C19–C20 Rectum	1	0.6	1.8	0.0	9.8	2.7	
C22 Liver	2	0.2	10.7	1.3	38.6 #	11.1	
C25 Pancreas	2	0.7	3.0	0.4	10.7	8.1	50.0
C33–C34 Lung	15	1.3	11.8	6.6	19.4 #	84.3	
C43 Malign. melanoma	1	0.6	1.6	0.0	9.1	2.4	
C50 Breast	13	5.1	2.6	1.4	4.4 #	48.6	
C51 Vulva	2	0.2	12.9	1.6	46.7 #	11.3	
C54 Corpus uteri	5	0.9	5.4	1.8	12.7 #	25.1	
C56 Ovary	2	0.6	3.2	0.4	11.4	8.4	
C73 Thyroid	3	0.3	10.3	2.1	30.1 #	16.6	
C76–C79 CUP	1	0.2	4.1	0.1	22.9	4.6	
C90 Mult. myeloma	1	0.2	5.6	0.1	31.2	5.0	
C91–C96 Leukaemia	2	0.2	9.4	1.1	33.9 #	11.0	
Not observed	0	2.7	0.0	0.0	1.4	-16.7	
All further malignancies	54	15.6	3.5	2.6	4.5 #	235.8	1.9
Patients		574					
Median age at next malignancy (years)		70.1					
Person-years		1628					
Mean observation time (years)		2.8					
Median observation time (years)		1.2					

The occurrence of further specified malignancy is statistically significant.

Average incidence (Germany 1987 standard population) 2007 - 2019: Males



Average incidence (Germany 1987 standard population) 2007 - 2019: Females





Figure 8a. Map of cancer incidence (german standard population) by county averaged for period 2007 to 2019. According to their individual incidence rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 1.5/100,000 WS N=485, females 1.4/100,000 WS N=492).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,462 female residents (averaged) in the period from 2007 to 2019 a total of 18 women were identified with newly diagnosed pulm. neuroend. tumor. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 1.8/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.9 and 3.3/100,000.

Standardized incidence ratio (SIR) 2007 - 2019: Males



Standardized incidence ratio (SIR) 2007 - 2019: Females




Figure 8b. Map of standardized incidence ratio (SIR) by county averaged for period 2007 to 2019. According to their individual SIR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=485, females N=492).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2019 a total of 18 women were identified with newly diagnosed pulm. neuroend. tumor. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 1.33. Though, the value of this parameter may vary with an underlying probability of 99% between 0.66 and 2.37, and is therefore not statistically striking.

MORTALITY

Table 9a

Annual cohorts: Incident cancers, follow-up status,
and deaths among the annual cohorts

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,
and from 4.10 to 4.92 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	12	83.3	6	50.0	100.0
1999	23	95.7	15	65.2	100.0
2000	21	100.0	12	57.1	83.3
2001	21	100.0	14	66.7	92.9
2002	25	92.0	14	56.0	85.7
2003	22	95.5	13	59.1	84.6
2004	29	96.6	16	55.2	93.8
2005	30	86.7	12	40.0	91.7
2006	30	93.3	13	43.3	100.0
2007	41	92.7	25	61.0	92.0
2008	61	98.4	30	49.2	96.7
2009	57	93.0	25	43.9	92.0
2010	51	96.1	29	56.9	100.0
2011	77	97.4	36	46.8	100.0
2012	73	97.3	42	57.5	92.9
2013	78	98.7	46	59.0	95.7
2014	96	96.9	50	52.1	98.0
2015	87	96.6	44	50.6	90.9
2016	97	100.0	34	35.1	82.4
2017	94	100.0	41	43.6	65.9
2018	96	100.0	32	33.3	31.3
2019	69	81.2	15	21.7	93.3
1998-2019	1190	96.1	564	47.4	88.1

Table 9b

Annual cohorts of incident cancers and deaths,
and cases deceased within the same year of being diagnosed with cancer

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002,
and from 4.10 to 4.92 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Deaths in same year n	Prop. deaths in same year %
1998	12	5	2	16.7
1999	23	8	1	4.3
2000	21	9	2	9.5
2001	21	6	1	4.8
2002	25	12	5	20.0
2003	22	9	3	13.6
2004	29	10	2	6.9
2005	30	15	3	10.0
2006	30	16	2	6.7
2007	41	17	6	14.6
2008	61	24	9	14.8
2009	57	25	10	17.5
2010	51	28	7	13.7
2011	77	34	12	15.6
2012	73	46	15	20.5
2013	78	39	13	16.7
2014	96	47	12	12.5
2015	87	64	23	26.4
2016	97	52	13	13.4
2017	94	47	13	13.8
2018	96	55	17	17.7
2019	69	37	7	10.1
1998-2019	1190	605	178	15.0

Table 9c

Annual cohorts of deaths, and proportion of cancer-related and non-cancer-related deaths

(with respect to registry area expansion from 2.65 to 4.10 m as of 2002, and from 4.10 to 4.92 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer- related %	Prop. non-cancer- related %	Prop. cancer recorded on death certificate %
1998	5	100.0		80.0
1999	8	75.0	25.0	100.0
2000	9	77.8	22.2	88.9
2001	6	83.3	16.7	80.0
2002	12	83.3	16.7	91.7
2003	9	88.9	11.1	88.9
2004	10	80.0	20.0	88.9
2005	15	73.3	26.7	85.7
2006	16	68.8	31.3	87.5
2007	17	70.6	29.4	81.3
2008	24	79.2	20.8	79.2
2009	25	96.0	4.0	95.8
2010	28	85.7	14.3	92.6
2011	34	85.3	14.7	85.3
2012	46	91.3	8.7	91.1
2013	39	89.7	10.3	92.3
2014	47	93.6	6.4	95.7
2015	64	87.5	12.5	84.4
2016	52	78.8	21.2	86.3
2017	47	78.7	21.3	87.0
2018	55	72.7	27.3	88.2
2019	37	78.4	21.6	94.1
1998–2019	605	83.1	16.9	88.6

Table 10a

Medians of age at death according to the grouping in Table 9
MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	3	71.0	71.0		64.7
1999	4	69.7	69.7		69.7
2000	3	77.7	77.7		77.7
2001	4	60.7	56.1	65.3	62.3
2002	9	68.0	69.1	65.9	68.5
2003	7	71.3	70.0	71.3	70.0
2004	5	57.1	57.1		57.1
2005	10	70.7	71.0	70.7	71.0
2006	13	71.8	75.2	56.1	71.8
2007	11	67.1	66.9	67.1	66.9
2008	17	72.1	69.9	74.2	69.9
2009	18	68.5	68.5		68.5
2010	18	66.3	67.3	65.3	67.7
2011	23	73.3	71.8	87.6	72.4
2012	29	68.7	68.0	83.5	68.3
2013	27	72.0	72.0	72.6	71.3
2014	22	69.7	69.7		69.7
2015	34	69.6	66.4	78.8	65.6
2016	26	73.1	68.8	75.9	72.6
2017	29	68.4	66.9	90.0	66.9
2018	27	71.8	71.9	68.7	76.3
2019	20	73.1	73.6	67.4	76.4
1998-2019	359	70.4	69.5	74.4	69.4

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 10b

Medians of age at death according to the grouping in Table 9
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (non-cancer-related) Years	Age at death (according to death certificate) Years
1998	2	74.6	74.6		74.6
1999	4	72.0	77.2	59.5	73.0
2000	6	78.6	76.6	78.7	79.0
2001	2	58.7	58.7		58.7
2002	3	72.9	72.9		72.9
2003	2	73.2	73.2		73.2
2004	5	74.9	73.8	75.5	76.2
2005	5	82.2	82.2	78.2	82.6
2006	3	80.4		80.4	80.4
2007	6	71.6	64.2	76.1	67.4
2008	7	77.3	72.4	84.1	72.4
2009	7	72.8	66.4	86.6	72.8
2010	10	76.2	73.2	80.6	73.2
2011	11	71.4	70.9	78.2	71.4
2012	17	70.3	69.7	87.3	69.7
2013	12	70.9	70.9	74.3	70.9
2014	25	70.8	70.4	83.6	70.6
2015	30	74.5	73.0	77.8	74.2
2016	26	76.1	73.6	86.6	73.6
2017	18	74.6	69.0	87.4	69.8
2018	28	69.2	71.1	67.8	75.5
2019	17	69.9	69.9	82.0	69.9
1998-2019	246	73.0	71.1	80.1	71.8

By 2018, Bavarians' life expectancy at birth is estimated at 79.3 years for boys and 83.8 years for girls.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11a

Mortality measures (cancer-related death) and mortality-incidence-index by year of death

MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	3	0.3	0.50	0.2	0.40	0.2	0.44	0.3	0.50
1999	4	0.4	0.36	0.2	0.32	0.3	0.36	0.4	0.36
2000	3	0.3	0.38	0.1	0.30	0.2	0.36	0.4	0.58
2001	3	0.3	0.21	0.2	0.19	0.2	0.22	0.3	0.21
2002	7	0.4	0.58	0.2	0.55	0.3	0.54	0.4	0.54
2003	6	0.3	0.67	0.2	0.62	0.3	0.69	0.4	0.73
2004	5	0.3	0.36	0.2	0.42	0.3	0.44	0.3	0.39
2005	8	0.4	0.47	0.2	0.31	0.3	0.38	0.5	0.51
2006	11	0.6	0.61	0.3	0.51	0.4	0.63	0.6	0.73
2007	8	0.4	0.33	0.2	0.29	0.3	0.30	0.3	0.30
2008	15	0.7	0.52	0.3	0.44	0.5	0.48	0.7	0.58
2009	18	0.8	0.69	0.4	0.57	0.6	0.59	0.7	0.68
2010	15	0.7	0.52	0.4	0.50	0.5	0.52	0.6	0.49
2011	19	0.8	0.48	0.4	0.42	0.6	0.43	0.8	0.49
2012	26	1.1	0.70	0.6	0.65	0.9	0.69	1.1	0.73
2013	25	1.1	0.60	0.5	0.53	0.8	0.55	1.0	0.60
2014	22	0.9	0.46	0.5	0.42	0.7	0.44	0.8	0.46
2015	28	1.2	0.68	0.6	0.65	0.9	0.65	1.1	0.68
2016	21	0.9	0.53	0.4	0.45	0.6	0.49	0.8	0.52
2017	24	1.0	0.51	0.5	0.52	0.7	0.52	0.9	0.51
2018	19	0.8	0.38	0.3	0.30	0.5	0.33	0.7	0.38
2019	17	0.7	0.53	0.3	0.53	0.5	0.54	0.6	0.53
1998-2019	307	0.7	0.52	0.4	0.46	0.5	0.49	0.7	0.52

Table 11b

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	2	0.2	0.33	0.1	0.24	0.1	0.27	0.2	0.38
1999	2	0.2	0.18	0.1	0.13	0.1	0.15	0.2	0.19
2000	4	0.3	0.31	0.1	0.15	0.2	0.20	0.3	0.28
2001	2	0.2	0.29	0.1	0.33	0.2	0.32	0.2	0.35
2002	3	0.2	0.23	0.1	0.16	0.1	0.18	0.1	0.23
2003	2	0.1	0.15	0.0	0.09	0.1	0.10	0.1	0.13
2004	3	0.2	0.20	0.1	0.11	0.1	0.14	0.1	0.17
2005	3	0.2	0.23	0.0	0.11	0.1	0.13	0.1	0.18
2006									
2007	4	0.2	0.24	0.1	0.21	0.1	0.22	0.1	0.22
2008	4	0.2	0.13	0.1	0.08	0.1	0.10	0.1	0.12
2009	6	0.3	0.19	0.1	0.17	0.2	0.17	0.2	0.17
2010	9	0.4	0.41	0.1	0.26	0.2	0.29	0.3	0.33
2011	10	0.4	0.27	0.2	0.18	0.2	0.20	0.3	0.25
2012	16	0.7	0.44	0.3	0.38	0.4	0.40	0.5	0.42
2013	10	0.4	0.28	0.2	0.23	0.3	0.24	0.3	0.26
2014	22	0.9	0.46	0.4	0.40	0.6	0.42	0.8	0.45
2015	28	1.2	0.61	0.5	0.50	0.7	0.53	0.9	0.56
2016	20	0.8	0.35	0.3	0.25	0.5	0.28	0.6	0.31
2017	13	0.5	0.28	0.2	0.28	0.3	0.28	0.4	0.27
2018	21	0.8	0.46	0.4	0.33	0.5	0.38	0.7	0.42
2019	12	0.5	0.32	0.2	0.25	0.3	0.28	0.4	0.29
1998-2019	196	0.4	0.33	0.2	0.25	0.3	0.28	0.3	0.31

Table 12

Age distribution of age at death (cancer-related) for period 2007-2019
 (incl. multiple malignancies)

Age at death Years	Cases			Males			Females		
	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
0-4									
5-9									
10-14									
15-19									
20-24									
25-29									
30-34									
35-39									
40-44	7	1.6	1.6	4	1.6	1.6	3	1.7	1.7
45-49	12	2.8	4.4	8	3.1	4.7	4	2.3	4.0
50-54	22	5.1	9.5	13	5.1	9.7	9	5.1	9.1
55-59	41	9.5	19.0	27	10.5	20.2	14	8.0	17.1
60-64	59	13.7	32.6	33	12.8	33.1	26	14.9	32.0
65-69	74	17.1	49.8	49	19.1	52.1	25	14.3	46.3
70-74	74	17.1	66.9	45	17.5	69.6	29	16.6	62.9
75-79	73	16.9	83.8	39	15.2	84.8	34	19.4	82.3
80-84	49	11.3	95.1	28	10.9	95.7	21	12.0	94.3
85+	21	4.9	100.0	11	4.3	100.0	10	5.7	100.0
All ages	432	100.0		257	100.0		175	100.0	

Table 13

Age-specific mortality (cancer-related) and proportion of all cancers
for period 2007-2019
(incl. multiple malignancies)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	Females Age- spec. MI-index	Males Age- spec. mortal.	Females Age- spec. MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4								
5- 9								
10-14								
15-19								
20-24								
25-29								
30-34								
35-39								
40-44	4	3	0.2	0.36	0.1	0.20	0.7	0.4
45-49	8	4	0.3	0.47	0.2	0.21	0.6	0.3
50-54	13	9	0.6	0.37	0.4	0.22	0.5	0.4
55-59	27	14	1.4	0.40	0.7	0.26	0.7	0.4
60-64	33	26	2.0	0.45	1.5	0.32	0.6	0.6
65-69	49	25	3.2	0.72	1.5	0.33	0.6	0.4
70-74	45	29	3.2	0.49	1.8	0.43	0.4	0.4
75-79	39	34	3.5	0.68	2.5	0.55	0.3	0.4
80-84	28	21	4.3	0.80	2.2	0.58	0.3	0.2
85+	11	10	2.6	1.10	1.0	0.91	0.1	0.1
All ages	257	175					0.4	0.3
Mortality								
Raw			0.9	0.53	0.6	0.36		
WS			0.4	0.48	0.2	0.28		
ES			0.6	0.50	0.4	0.31		
BRD-S			0.8	0.53	0.5	0.33		
PYLL-70								
per 100,000			4.6		2.9			
ES			3.9		2.4			
AYLL-70			9.1		9.4			

Table 14a

Further malignancies in deaths in period 1998-2019
MALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C03-C06 Oral cavity	2	2.0	2	100.0				
C09-C10 Oropharynx	4	4.1	2	50.0	1	25.0	1	25.0
C15 Oesophagus	1	1.0	1	100.0				
C16 Stomach	6	6.1	3	50.0	1	16.7	2	33.3
C18 Colon	6	6.1	2	33.3	3	50.0	1	16.7
C19-C20 Rectum	5	5.1	4	80.0			1	20.0
C22 Liver	5	5.1			3	60.0	2	40.0
C23-C24 Bile	1	1.0					1	100.0
C33-C34 Lung	15	15.3			6	40.0	9	60.0
C43 Malign. melanoma	7	7.1	6	85.7			1	14.3
C44 Skin others	9	9.2	5	55.6	1	11.1	3	33.3
C48 Peritoneal	1	1.0					1	100.0
C50 Breast	1	1.0	1	100.0				
C61 Prostate	15	15.3	13	86.7			2	13.3
C62 Testis	2	2.0	2	100.0				
C64 Kidney	4	4.1	3	75.0			1	25.0
C66 Ureter	1	1.0					1	100.0
C67 Bladder	6	6.1	3	50.0	1	16.7	2	33.3
C69 Eye melanoma	1	1.0	1	100.0				
C70-C72 CNS cancer	2	2.0	1	50.0			1	50.0
C81 Hodgkin lymphoma	1	1.0	1	100.0				
C82-C85 NHL	2	2.0	2	100.0				
C90 Mult. myeloma	1	1.0					1	100.0
All further malignancies	98	100.0	52	53.1	16	16.3	30	30.6

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 14b

Further malignancies in deaths in period 1998-2019
FEMALES

Diagnosis	Total n	Total %↓	Pre n	Pre ←%	Syn- chron ±30d n	Syn- chron ±30d ←%	Post n	Post ←%
C07-C08 Salivary gland	1	1.0	1	100.0				
C09-C10 Oropharynx	2	2.0	2	100.0				
C15 Oesophagus	1	1.0	1	100.0				
C16 Stomach	2	2.0			2	100.0		
C17 Small intestine	1	1.0	1	100.0				
C18 Colon	13	13.1	10	76.9	1	7.7	2	15.4
C19-C20 Rectum	3	3.0	3	100.0				
C21 Anus/canal	1	1.0	1	100.0				
C22 Liver	4	4.0	1	25.0	1	25.0	2	50.0
C25 Pancreas	3	3.0			2	66.7	1	33.3
C32 Larynx	1	1.0	1	100.0				
C33-C34 Lung	13	13.1			5	38.5	8	61.5
C43 Malign. melanoma	3	3.0	3	100.0				
C44 Skin others	2	2.0	2	100.0				
C50 Breast	24	24.2	19	79.2	2	8.3	3	12.5
C51 Vulva	1	1.0					1	100.0
C53 Cervix uteri	3	3.0	1	33.3	2	66.7		
C54 Corpus uteri	5	5.1	5	100.0				
C56 Ovary	3	3.0	2	66.7	1	33.3		
C64 Kidney	4	4.0	3	75.0	1	25.0		
C67 Bladder	2	2.0	2	100.0				
C73 Thyroid	3	3.0	2	66.7	1	33.3		
C74-C80 Cancer others	1	1.0	1	100.0				
C90 Mult. myeloma	2	2.0	1	50.0			1	50.0
C91-C96 Leukaemia	1	1.0					1	100.0
All further malignancies	99	100.0	62	62.6	18	18.2	19	19.2

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a further malignancy.

Table 15

Age-specific mortality (cancer-related) and proportion of all cancers
for period 2007-2019
(**First primaries only ***)

Age at death Years	Males n	Females n	Males Age- spec. mortal. MI-index	Females Age- spec. mortal. MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4						
5- 9						
10-14						
15-19						
20-24						
25-29						
30-34						
35-39						
40-44	4	2	0.2	0.36	0.1	0.14
45-49	7	4	0.3	0.50	0.2	0.24
50-54	12	6	0.5	0.38	0.3	0.21
55-59	26	13	1.3	0.44	0.7	0.34
60-64	27	18	1.7	0.47	1.0	0.29
65-69	40	12	2.6	0.74	0.7	0.23
70-74	32	15	2.3	0.52	0.9	0.38
75-79	29	21	2.6	0.69	1.5	0.54
80-84	13	11	2.0	0.62	1.1	0.42
85+	6	5	1.4	2.00	0.5	0.71
All ages	196	107			0.4	0.2
Mortality						
Raw			0.7	0.53	0.3	0.30
WS			0.3	0.49	0.2	0.24
ES			0.5	0.51	0.2	0.26
BRD-S			0.6	0.53	0.3	0.28
PYLL-70						
per 100,000			4.2		2.2	
ES			3.5		1.8	
AYLL-70			9.5		10.5	

* See corresponding tables with multiple malignancies.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers for period 2007-2019 (Single primaries only *)

Age at death Years	Males n	Females n	Males Age- spec. mortal.	Males MI-index	Females Age- spec. mortal.	Females MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4								
5- 9								
10-14								
15-19								
20-24								
25-29								
30-34								
35-39								
40-44	4	2	0.2	0.36	0.1	0.15	0.8	0.3
45-49	7	4	0.3	0.54	0.2	0.27	0.6	0.3
50-54	12	5	0.5	0.41	0.2	0.19	0.5	0.2
55-59	26	11	1.3	0.45	0.6	0.33	0.7	0.4
60-64	25	16	1.5	0.47	0.9	0.27	0.5	0.4
65-69	39	11	2.6	0.75	0.7	0.24	0.6	0.2
70-74	30	12	2.1	0.50	0.7	0.33	0.4	0.2
75-79	25	18	2.3	0.64	1.3	0.47	0.3	0.3
80-84	12	10	1.8	0.60	1.0	0.42	0.2	0.2
85+	5	5	1.2	1.67	0.5	0.71	0.1	0.1
All ages	185	94					0.4	0.2
Mortality								
Raw			0.6	0.52	0.3	0.29		
WS			0.3	0.49	0.1	0.23		
ES			0.5	0.51	0.2	0.25		
BRD-S			0.6	0.52	0.2	0.27		
PYLL-70								
per 100,000			4.1		2.0			
ES			3.5		1.6			
AYLL-70			9.6		10.6			

* See corresponding tables with multiple malignancies.

BNET: Bronchopulmonary neuroendocrine tumor (excl. SCLC)

Age distribution and age-specific mortality 2007 - 2019 (Males: 257, Females: 175)





Figure 17. Distribution of age at death (bars; males: mean=66.7 yrs, median=67.9 yrs; females: mean=67.3 yrs, median=68.5 yrs) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at pulm. neuroend. tumor-related death (see Table 10) should be considered.

Average mortality (Germany 1987 standard population) 2007 - 2019: Males



Average mortality (Germany 1987 standard population) 2007 - 2019: Females





Figure 18a. Map of cancer mortality (german standard population) by county averaged for period 2007 to 2019. According to their individual mortality rates, the counties are displayed in different red and blue hues, being the fine white color attributed to the population mean (males 0.8/100,000 WS N=257, females 0.5/100,000 WS N=175).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,462 female residents (averaged) in the period from 2007 to 2019 a total of 6 women died from pulm. neuroend. tumor. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.5/100,000 (german standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.1 and 1.5/100,000.

Standardized mortality ratio (SMR) 2007 - 2019: Males



Standardized mortality ratio (SMR) 2007 - 2019: Females




Figure 18b. Map of standardized mortality ratio (SMR) by county averaged for period 2007 to 2019. According to their individual SMR values, the counties are displayed in different red and blue hues, being the fine white color attributed to the population overall of 1.0 (males N=257, females N=175).

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 67,153 female residents (averaged) in the period from 2007 to 2019 a total of 6 women died from pulm. neuroend. tumor. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 1.25. Though, the value of this parameter may vary with an underlying probability of 99% between 0.32 and 3.27, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases, where applicable. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the cancer-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head&neck and lung).

The ratio of mortality and incidence (mortality-to-incidence ratio, **MIR, MI-Index**) is a statistical index that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MIR. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

MCR	Munich Cancer Registry (Tumorregister München)
GEKID	Association of Population-based Cancer Registries in Germany (Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
SEER	Surveillance, Epidemiology, and End Results (USA)
DCO	Death certificate only
BRD-S	German (FRG) standard population
ES	European standard population (old)
WS	World standard population
SIR	Standardized incidence ratio
CI	Confidence interval
EAR	Excess absolute risk = excess cancer cases (O - E) per 10,000 person-years
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
SMR	Standardized mortality ratio
MI-index	Ratio of mortality to incidence, MIR
FRG	Federal Republic of Germany

Recommended Citation

Munich Cancer Registry. BNET: Pulm. neuroend. tumor - Incidence and Mortality [Internet]. 2021 [updated 2021 Jan 26; cited 2021 Mar 1]. Available from: <https://www.tumorregister-muenchen.de/en/facts/base/bhBNETE-BNET-Pulm.-neuroend.-tumor-incidence-and-mortality.pdf>

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.